BullishWhales · Analysts · Analyst Profile
Analyst rating accuracy & track record
Li Watsek does not yet have enough resolved 12-month calls to carry a published score. Check back as their ratings mature.
Ratings & price targets
| Stock | Rating | Price target | Rated | 12-mo vs sector | PT hit |
|---|---|---|---|---|---|
 ZLABZai Lab Ltd | Buy | — | Mar 2025 | −52.6% | — |
 ACRVAcrivon Therapeutics, Inc. Common Stock | Buy | — | Mar 2025 | −46.0% | — |
 TARAProtara Therapeutics Inc | Buy | — | Mar 2025 | +17.9% | — |
| ACRVAcrivon Therapeutics, Inc. Common Stock | Buy | — | Jan 2025 | −75.0% | — |
 ALXOAlx Oncology Holdings | Buy | — | Jan 2025 | −13.9% | — |
| ALXOAlx Oncology Holdings | Buy | — | Dec 2024 | −19.7% | — |
 KURAKura Oncology Inc | Buy | — | Dec 2024 | −2.2% | — |
| KURAKura Oncology Inc | Buy | — | Nov 2024 | −2.4% | — |
| ALXOAlx Oncology Holdings | Buy | — | Nov 2024 | −10.4% | — |
| ALXOAlx Oncology Holdings | Buy | — | Aug 2024 | −64.9% | — |
| ALXOAlx Oncology Holdings | Buy | — | May 2024 | −90.6% | — |
 CRISCuris Inc | Buy | — | May 2024 | −74.9% | — |
| ALXOAlx Oncology Holdings | Buy | — | Apr 2024 | −97.7% | — |
 CRVSCorvus Pharmaceuticals Inc | Buy | — | Apr 2024 | +69.4% | — |
| CRVSCorvus Pharmaceuticals Inc | Buy | $4.00 | Sep 2023 | +111.8% | Hit |
| CRVSCorvus Pharmaceuticals Inc | Buy | $4.00 | May 2023 | +5.9% | Hit |
 FATEFate Therapeutics Inc | Buy | $45.00 | Nov 2022 | −85.8% | Miss |
| CRVSCorvus Pharmaceuticals Inc | Buy | $8.00 | Dec 2021 | −74.7% | Miss |
Go to
Browse the full analyst leaderboardHow analyst accuracy is scored
Every score, Win %, PT Hit % and rank is an estimate Bullish Whales calculates from its own data and may not be 100% accurate or complete. Returns are measured in excess of each rated stock's own sector over the 12 months after each call. Past performance does not guarantee future results, and nothing here is a recommendation to buy or sell any security.